#China #Beijing #Jenscare #LuX-Valve #Ken-Valve

Jenscare Scientific Co., Ltd. Achieves Major Milestones in 2025H1 Interim Results

Jenscare Scientific Co., Ltd. has recently released its interim results for the first half of 2025, announcing significant accomplishments in its product portfolio. The company, known for its innovative medical devices, particularly in the realm of transcatheter valve replacement (TTVR), has reported substantial progress across multiple areas. The results, released on September 1, 2025, underline Jenscare's commitment to addressing complex heart valve diseases with its pioneering technologies.

Notable Achievements and Global Expansion

In the first six months of 2025, Jenscare made notable strides in its interventional treatments for tricuspid, aortic, and mitral valve diseases. This ongoing progress has enabled the company to create a diverse and high-potential product portfolio. The highlights of the interim results showcase the company’s strategy to expand its global footprint while enhancing the clinical applications of its products.

The LuX-Valve Plus TTVR system is at the forefront of this momentum, having achieved key milestones in its global registrations and clinical trials across China, Europe, and the United States. In China, Jenscare’s multicenter clinical trial for the LuX-Valve Plus is currently in the long-term follow-up phase, showing excellent results. Furthermore, the randomized controlled trial for optimized medical therapy has completed participant enrollment, and the application for NMPA registration is in the review process.

In Europe, the LuX-Valve Plus has shown promising outcomes in the TRINITY Study, and the recent 30-day follow-up results, presented at EuroPCR 2025, indicate successful clinical outcomes for patients with various annular sizes. The outcomes from this study will be crucial as they continue toward CE Marking and regulatory approval.

The LuX-Valve Plus's participation in the FDA’s Total Product Life Cycle Advisory Program in the U.S. also underscores Jenscare's focus on fulfilling regulatory requirements for market entry, a move that could expedite its commercialization pipeline further.

Rapid Advancement of Ken-Valve Commercialization

Another highlight from Jenscare’s interim results is the swift progression of the Ken-Valve TAVR system. Since its approval by NMPA in early 2025, the system has recorded significant hospital adoption and implantations across various regions. This product has received overwhelming positive feedback due to its innovative design and efficacy in treating severe aortic regurgitation (AR), paired with aortic stenosis (AS).

The Ken-Valve’s unique features cater to a wide range of anatomical challenges often faced by patients. Its design promises both enhanced safety during procedures and reduced operation time, with instances of the device being implanted in under 10 minutes. Such operational efficiency is expected to solidify its presence in the market and enhance profitability for Jenscare.

The commercialization efforts of the Ken-Valve will continue, with the company leveraging its supply chain strengths and tailored marketing strategies to sustain growth and profitability.

JensClip TMVr System Moves Forward

In addition to the aforementioned products, Jenscare has submitted its NMPA registration application for the JensClip TMVr system, which is entering the registration stage. The recent one-year follow-up results from EuroPCR 2025 are promising, displaying encouraging safety and efficacy outcomes.

The company’s global outreach is expected to accelerate as successful pre-commercialization implants have been conducted overseas, demonstrating the product's effectiveness and performance across diverse healthcare settings. The pursuit of CE Marking for JensClip further supports Jenscare’s strategy for building an international presence.

Strategic Global Initiatives

Jenscare's future plans involve an extensive promotional strategy aimed at expanding its market share and reinforcing its brand recognition in the medical community. By leveraging key opinion leaders (KOLs) and professional networks, the company will disseminate knowledge regarding its innovative devices, improving procedural skills through ongoing education and training.

A robust sales network across China and preparation for global markets indicate Jenscare’s agility in responding to market demands and evolving healthcare needs.

Commitment to Innovation and Growth

Overall, Jenscare Scientific Co., Ltd. continues to demonstrate strong operational performance with high-quality growth indicators. In the recent interim results, the company reported revenues of RMB 26 million (approximately US$ 3.6 million), alongside robust profit margins. With significant resources aimed at improving product development and commercialization, Jenscare is on track to fulfill its mission of becoming a leading player in the medical device sector, particularly in addressing cardiology needs worldwide. As it continues to innovate and expand its product portfolio, Jenscare aims to effectively tackle urgent clinical demands in structural heart disease treatments.

Through strategic enhancements in operational efficiency and market engagement, Jenscare is well-positioned for sustained success, reinforcing its commitment to advancing medical technology globally.